Cereboost (American Ginseng Extract) and Brain Function

NCT07255755 | Recruiting

• 2 other identifiers: R211952IRAS355890
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 2

Brief Summary

The study will assess the immediate, short-term benefits of a single dose of a supplement containing 200mg of Panax quinquefolius (American Ginseng) on cognition (brain function) in healthy young adults. To understand the effect this product may have, the participants will complete a series of questionnaires and cognitive tests (tests of memory and brain function) at set intervals across a 6-hour period. Blood samples will also be collected to assess the impact of the study product on the participants.

Conditions

Attention; Cognition

Keywords

American Ginseng; Cereboost

Outcome Measures

Primary Outcomes (1)

• Measure of Attention

  Measured by the Attentional Network Task (ANT), expressed by accuracy score (%correct) at 6 hours post consumption

  Baseline, 2-hours, 4-hours and 6-hours post intervention

Secondary Outcomes (6)

• Measure of Cognition (Executive function)

  Baseline, 2-hours, 4-hours and 6-hours post intervention

• Measure of Cognition (Reaction Time)

  Baseline, 2-hours, 4-hours and 6-hours post intervention

• Measure of Mood State

  At the beginning and end of the cognitive task batteries at baseline, and at 2-hours, 4-hours and 6-hours post intervention

• Measure of Subjective Sleepiness

  At the beginning and end of the cognitive task batteries at baseline, and at 2-hours, 4-hours and 6-hours post intervention

• Measure of Subjective Mental Fatigue

  At the beginning and end of the cognitive task batteries at baseline, and at 2-hours, 4-hours and 6-hours post intervention

Study Arms (2)

Placebo

PLACEBO COMPARATOR

A placebo capsule (containing maltodextrin)

Dietary Supplement: Placebo product

Study Product

EXPERIMENTAL

Study product capsule containing 200mg American Ginseng extract (Cereboost TM)

Dietary Supplement: American Ginseng extract

Interventions

Placebo product DIETARY_SUPPLEMENT

Placebo capsules, identical in appearance to active treatment, but only containing maltodextrin

Placebo

American Ginseng extract DIETARY_SUPPLEMENT

Cereboost TM capsules delivering 200 mg of Panax quinquefolius extract standardised for ginsenosides (10-12%)

Study Product

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Be able to give written informed consent.
• Be between 18-40 years, inclusive.
• Depression Anxiety and Stress Scale scores (DASS-21):
• Depression ≤9
• Anxiety ≤7
• Stress ≤14
• Willing to refrain from alcohol consumption 24-hours prior to assessment visits.
• Willing to refrain from caffeine consumption (including but not limited to energy drinks, soda, coffee…) on the morning of the assessment visit.
• Non-smokers and non-vapers
• Willing to consume the Study Product (SP).
• Willing to attend the study visit in an overnight fasted state, having followed a low-polyphenol diet for 48 h.
• Fluent in written and spoken English

You may not qualify if:

• Participants will be excluded from the study if they meet any of the following criteria:
• Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
• Has food allergies or other issues with foods that would preclude intake of the Study Products.
• Not willing to consume gelatine from bovine/porcine source
• Has a BMI ≤18.5 or ≥30kg/m2
• Blood pressure \>140/90 mmHg
• Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results.
• Excluded health conditions include:
• Cognitive disorders in the past 12 months.
• Current or past history of a major neuropsychiatric disorder, including: bipolar disorder, schizophrenia and schizotypal personality disorder
• Current or past history of a major neurological condition.
• Gastrointestinal disorders (e.g. IBS/IBD)
• ADHD (attention deficit hyperactivity disorder)
• Learning disabilities and difficulties
• Current, uncorrected, vision or hearing impairment

Sponsors & Collaborators

• University of East Anglia: lead
• Givaudan France Naturals: collaborator
• Atlantia Food Clinical Trials: collaborator

Study Sites (2)

Quadram Insitute Clinical Research Facility

Norwich, Norfolk, NR4 7UQ, United Kingdom

RECRUITING

University of East Anglia

Norwich, Norfolk, NR4 7UQ, United Kingdom

RECRUITING

MeSH Terms

Interventions

Asian ginseng

Study Officials

• David Vauzour, PhD

  University of East Anglia

  PRINCIPAL INVESTIGATOR

Central Study Contacts

David Vauzour, PhD

CONTACT

+441603591732; D.Vauzour@uea.ac.uk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2025
• First Posted: December 1, 2025
• Study Start: December 1, 2025
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2027
• Last Updated: December 9, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

GB (2)